Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension

American Journal of Ophthalmology

Volumn 135, Issue 2, 2003, Pages 138-143

  Day, Douglas G ^a   Schacknow, Paul N ^b   Wand, Martin ^c   Sharpe, Elizabeth D ^d   Stewart, Jeanette A ^e   Leech, Jessica ^e   Stewart, William C ^e,f  

^a Atlanta Research Company   (United States)

^b Palm Beach Eye Foundation Inc   (United States)

^c PC ^*  (United States)

^d Glaucoma Consult/Ctr for Eye Res   (United States)

^e University of South Carolina   (United States)

^f UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; TIMOLOL; TIMOLOL MALEATE; UNOPROSTONE ISOPROPYL ESTER;

ABDOMINAL PAIN; ADRENAL TUMOR; ARTICLE; BENIGN TUMOR; BLEPHARITIS; BURN; CHEEK; CHEMOSIS; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE PAIN; FOREIGN BODY; HUMAN; INTRAOCULAR HYPERTENSION; MEDICINE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; REDUCTION; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VITREOUS BODY DETACHMENT;

ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DINOPROST; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; SAFETY; SULFONAMIDES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0037310644     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01887-1     Document Type: Article

References (17)

1. Clineschmidt C.M., Williams R.D., Snyder E., Adamsons I.A. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology. 106:1999;17-24.
2. Boyle J.E., Ghosh K., Gieser D.K., Adamsons I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 106:1999;10-16.
3. Nordmann J.P., Mertz B., Yannoulis N.C., Schwenniger C., Kapik B., Shams N. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. Six month data. Am J Ophthalmol. 133:2002;1-10.
4. Orzalesi N., Rossetti L., Invernizzi T., Bottoli A., Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 41:2000;2566-2573.
5. Lippa E.A., Schuman J.S., Higginbotham E.J., et al. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology. 98:1991;308-312.
6. Book SA. Essentials of statistics. New York: McGraw Hill, 1978:117-122,205-215.
7. Mundorf T.K., Cate E.A., Sine C.S., Otero D.W., Stewart J.A., Stewart W.C. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther. 14:1998;129-135.
8. Duff G.R. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressure. Acta Ophthalmologica. 65:1987;618-621.
9. Konstas A.G.P., Lake S., Maltezos A.C., Holmes K.T., Stewart W.C. 24 hour intraocular pressure reduction with latanoprost compared to pilocarpine as third line therapy in exfoliation glaucoma. Eye. 15:2001;59-62.
10. Stewart W.C., Day D.G., Stewart J.A., Schuhr J., Latham K.E. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 131:2001;631-635.
11. Siegel S. Non parametric statistics. Series in psychology. 1956;63-67 McGraw Hill, New York.
12. Stewart W.C. New perspectives in the medical treatment of glaucoma. Curr Opin. 127:1999;142-147.
13. Hutzelmann J., Owens S., Shedden A., Adamsons I., Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 82:1998;1249-1253.
14. Sakuri M., Araie M., Oshika T., et al. Effects of topical application of UF-21, a novel prostaglandin-related compound, on aqueous humor dynamics in normal human eyes. J Ophthalmol. 35:1991;156-165.
15. Stewart W.C., Mundorf T., Haque R., Brown A., Kapik B., Shams N. Comparison of the IOP-lowering efficacy and safety of the docosanoid unoprostone 0.15% versus timolol maleate 0.5% dosed twice daily for 6 months in patients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 42:2001;S557.
16. Susanna R. Jr, Giampani J. Jr, Borges A.S., Vessani R.M., Jordao M.L. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 108:2001;259-263.
17. Aung T., Chew P.T.K., Yip C.C., et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 131:2001;636-642.